4 Analysts Assess Enanta Pharma: What You Need To Know

4 位分析师评估 Enanta 制药：您需要了解的内容

Benzinga · 2024/11/26 21:01

In the last three months, 4 analysts have published ratings on Enanta Pharma (NASDAQ:ENTA), offering a diverse range of perspectives from bullish to bearish.

在过去三个月里，4位分析师对Enanta Pharma（纳斯达克：ENTA）进行了评级，提供了从看好到看淡的多元化观点。

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

下表提供了他们最近的评级快照，展示了情绪在过去30天中的演变情况，并将其与之前的月份进行比较。

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $23.0, along with a high estimate of $27.00 and a low estimate of $21.00. This current average represents a 1.08% decrease from the previous average price target of $23.25.

分析师提供了更深入的见解，已确定了12个月的目标价位，显示了平均目标为$23.0，最高估价为$27.00，最低估价为$21.00。当前的平均值相比于之前的$23.25的平均目标价位下降了1.08%。

Deciphering Analyst Ratings: An In-Depth Analysis

分析师评级解读：深入分析

An in-depth analysis of...

4 Analysts Assess Enanta Pharma: What You Need To Know

4 Analysts Assess Enanta Pharma: What You Need To Know

风险及免责提示

声明